Tag Archives: Public Citizen’s Access to Medicines project

Exposed: How Pfizer Exploits Secretive Vaccine Contracts to Strong-Arm Governments

“Pfizer has used its monopoly on a lifesaving vaccine to extract concessions from desperate governments,” said the report’s author, urging action from the Biden administration.

By Jessica Corbett, staff writer for Common Dreams. Published 10=19-2021

Pfizer is under fire for secretive contracts with countries buying its Covid-19 vaccines. Screenshot: ABC News

Pfizer has used its position as a producer of one of the leading Covid-19 vaccines to “silence governments, throttle supply, shift risk, and maximize profits” through secret contracts with countries around the world, according to a Public Citizen report published Tuesday.

“Behind closed doors, Pfizer wields its power to extract a series of concerning concessions from governments,” report author Zain Rizvi, law and policy researcher at Public Citizen’s Access to Medicines program, said in a statement. “The global community cannot allow pharmaceutical corporations to keep calling the shots.” Continue reading

Share Button

‘Absolute Robbery’: Gilead Announces $3,120 Price Tag for Covid-19 Drug Developed With $70 Million in Taxpayer Support

“Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic. Beyond disgusting,” said Sen.Bernie Sanders.

By Jake Johnson, staff writer for Common Dreams. Published 6-29-2020

Photo: Ivan Radic/flickr/CC

Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.

Peter Maybarduk, director of Public Citizen’s Access to Medicines Program, called Gilead’s pricing—which works out to around $520 per dose for non-government buyers like hospitals—”an offensive display of hubris and disregard for the public” and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all. Continue reading

Share Button

‘This Is a Massive Scandal’: Trump FDA Grants Drug Company Exclusive Claim on Promising Coronavirus Drug

“It is insane and unacceptable,” said Bernie Sanders. “We will not tolerate profiteering. Any treatment or vaccine must be made free for all.”

By Julia Conley, staff writer for Common Dreams. Published 3-24-2020

Coronavirus. Photo: CDC

As healthcare providers across the U.S. desperately attempt to treat a rapidly growing number of patients with the coronavirus, a pharmaceutical company with ties to the Trump administration has been granted exclusive status for a drug it is developing to treat the illness—a potential windfall for the company that could put the medication out of reach for many Americans.

As The Intercept reported Monday, the Food and Drug Administration granted Gilead Sciences “orphan” drug status for remdesivir, one of several drugs being tested as potential treatments for the coronavirus, officially known as COVID-19. The designation is generally reserved for drugs that treat rare illnesses affecting fewer than 200,000 Americans—but companies can be eligible if the designation, as in this case of a rapidly spreading virus, is made before a disease spreads beyond that limit. Continue reading

Share Button

Why Are Drug Prices Rising So Much? Pharma Exec Admits ‘No Other Rationale’ But Profit-Making

“The industry executive said the quiet part out loud,” said one outside expert in response. “Price-gouging is central to the industry business model.”

By Andrea Germanos, staff writer for Common Dreams. Published 11-28-2019

Photo: Liz McGregor

Corporations’ quest for profits is what “is driving up drug prices and nothing more.”

That’s according to Dennis Bourdette, M.D., chair of neurology in the Oregon Health and Science University (OHSU) School of Medicine, who co-authored a study published Monday that sought to find out companies’ rationale for the escalating prices on medications for patients with multiple sclerosis. Continue reading

Share Button